Interleukin‐6 blockade treatment for COVID‐19 associated cytokine release syndrome in a patient with poorly controlled chronic myeloid leukaemia
- Resource Type
- Source
- British Journal of Haematology
- Subject
Male Letter Coronavirus disease 2019 (COVID-19) viruses Pneumonia, Viral medicine.disease_cause Chronic myeloid leukaemia Antibodies, Monoclonal, Humanized 03 medical and health sciences chemistry.chemical_compound Betacoronavirus 0302 clinical medicine Immune system Tocilizumab Leukemia, Myelogenous, Chronic, BCR-ABL Positive medicine Humans Letters Interleukin 6 Pandemics Coronavirus biology business.industry Interleukin-6 SARS-CoV-2 virus diseases COVID-19 Hematology biochemical phenomena, metabolism, and nutrition Middle Aged medicine.disease Blockade Cytokine release syndrome chemistry 030220 oncology & carcinogenesis Immunology biology.protein business Coronavirus Infections Cytokine Release Syndrome Tomography, X-Ray Computed Immunosuppressive Agents 030215 immunology - Language
- English
- ISSN
- 1365-2141
0007-1048